"I am working for the Washington State Liquor Control Board as a consultant to develop the standards for certifying laboratories that will provide quality control and potency testing for Cannabis and related products under I502. Washington State will have the highest level of quality control in the US as well as most of Europe. These certification standards are based in part on the American Herbal Pharmacopoeia monograph on Cannabis, going to press this week!" - Insider
KannaLife is in a truly opportunistic position in that it has licensed from NIH-OTT on an exclusive basis the right to develop its intellectual property into a novel therapeutic treatment for HE with a market potential in the range of $500 million to $1 billion dollars. Kannalife’s proposed target drug candidate would be considered part of a new class of pharmaceuticals designed as neuroprotectants with additional potential therapeutic benefits in reducing oxidative stress.
Kannalife’s pre-clinical research being performed at the Pennsylvania Biotechnology Center located in Doylestown, PA. Kannalife’s R&D at Doylestown is focused on the use of Cannabidiol (CBD) and other potential cannabinoids analogs in selecting its target drug candidate for an Investigational New Drug Application (IND), and possibly an Abbreviated New Drug Application (ANDA) with the United States Food and Drug Administration (FDA).
As part of its approach to standardization, KannaLife is marketing a proprietary packaging system to be marketed and sold as under the KannaPak trademark. This system provides for standardized testing, labeling and packaging that has already gained early and timely acceptance from several sizeable industry experts, licensees, and producers in Colorado, California, New Jersey and Connecticut.
So now what you have with KannaLife is an extension of the over-the-counter (OTC) products of MJNA and CANV such as CanChew Gum andReal Scientific Hemp Oil (RSHO). KannaLife rounds out the health and wellness corporate profiles of both MJNA and CANV by adding a phyto-medical and pharmaceutical company to its portfolio of investments. It is likely that there will be dynamic and synergistic interplay between all of MJNA and CANV related entities, including but not limited to, quality and standardizations processes, which can flow between the various entities, thus reducing R&D costs and accelerating products to market.
Conclusion
KannaLife has assembled what looks to be a very strong advisory board as well as a team of well regarded scientific professionals with strong pharmaceutical experience. Through South Park Ventures LLC, KannaLife has positioned itself to provide expertise in efficacy and standardization of product development.
In light of these positive developments, it wouldn’t be surprising if KannaLife proved to be the next breakout pharmaceutical company. You may want to adjust your portfolios accordingly. - source
News 
Market Data 
Discover 
